These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 5379868)
41. [Leprosy research]. Luger A Wien Klin Wochenschr; 1971 Mar; 83(10):161-5. PubMed ID: 4327066 [No Abstract] [Full Text] [Related]
42. Treatment of leprosy with a phenazine derivative (B 663 or G 30 320)--clofazimine. Gatti JC; Cardama JE; Balina LM; Crespi HG; Bianchi O; Santabaya E; Farina MH Lepr Rev; 1970 Apr; 41(2):89-92. PubMed ID: 5453084 [No Abstract] [Full Text] [Related]
43. The effects of tilorone on mycobacterial infections of mice. Levy L; Aizer F; Ng H; Welch TM Lepr Rev; 1978 Sep; 49(3):215-22. PubMed ID: 357869 [No Abstract] [Full Text] [Related]
44. Leprosy research at the National Institutes of Health: experience with B.663 in the treatment of leprosy. Williams TW; Mott PD; Wertlake PT; Rubio JB; Adler RC; Hill GJ; Suarez GP; Knight V Int J Lepr; 1965; 33(3):Suppl:767-77. PubMed ID: 5322715 [No Abstract] [Full Text] [Related]
46. Clofazimine for leprosy and Mycobacterium avium complex infections. Med Lett Drugs Ther; 1987 Aug; 29(746):77-8. PubMed ID: 3614089 [No Abstract] [Full Text] [Related]
47. Acute abdomen in a patient treated with lamprene. Jagadeesan K; Visweswaran MK; Iyer KH Int Surg; 1975 Apr; 60(4):208-9. PubMed ID: 1091577 [TBL] [Abstract][Full Text] [Related]
48. Treatment of cutaneous infection due to Mycobacterium ulcerans. Song M; Vincke G; Vanachter H; Benekens J; Achten G Dermatologica; 1985; 171(3):197-9. PubMed ID: 2416603 [TBL] [Abstract][Full Text] [Related]
49. Story behind the clinical trial of B.663 in leprosy. Chang YT Int J Lepr Other Mycobact Dis; 1967; 35(1):78-80. PubMed ID: 6067040 [No Abstract] [Full Text] [Related]
50. Sporotrichoid Mycobacterium marinum infection in diabetes. Chemotherapy with rifampin and ethambutol. Bodaness RS N Y State J Med; 1978 Oct; 78(12):1935-6. PubMed ID: 279836 [No Abstract] [Full Text] [Related]
51. [A case of atypical mycobacteriosis due to M. fortuitum (author's transl)]. Iizima M; Takizawa K; Ohara K; Umeda T; Okuzumi K; Shimizu K; Takahashi S Nihon Hifuka Gakkai Zasshi; 1978 May; 88(6):389-97. PubMed ID: 307624 [No Abstract] [Full Text] [Related]
53. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae. Levy L; Shepard CC; Fasal P Am J Trop Med Hyg; 1972 May; 21(3):315-21. PubMed ID: 4554496 [No Abstract] [Full Text] [Related]
54. The use of B 663 (clofazimine) in the treatment of Chinese leprosy patients with chronic reaction. Warren AG Lepr Rev; 1970 Apr; 41(2):74-82. PubMed ID: 5453082 [No Abstract] [Full Text] [Related]
55. Studies on sulfone resistance in leprosy. 2. Treatment with a riminophenazine derivative (B.663). Pettit JH; Rees RJ Int J Lepr Other Mycobact Dis; 1966; 34(4):391-7. PubMed ID: 6006070 [No Abstract] [Full Text] [Related]
56. Skin lesions caused by Mycobacterium haemophilum. Davis BR; Brumbach J; Sanders WJ; Wolinsky E Ann Intern Med; 1982 Nov; 97(5):723-4. PubMed ID: 6753680 [No Abstract] [Full Text] [Related]
57. Clofazimine in leprosy. Browne SG Br Med J; 1972 Feb; 1(5798):506-7. PubMed ID: 4550304 [No Abstract] [Full Text] [Related]
58. Clofazimine in leprosy. Schulz EJ Br Med J; 1972 Mar; 1(5802):749. PubMed ID: 5015339 [No Abstract] [Full Text] [Related]